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Abstract: In this study, we elucidated the inhibitory effect of fucoidan from marine brown 
algae on the lipid accumulation in differentiated 3T3-L1 adipocytes and its mechanism. 
The treatment of fucoidan in a dose-dependent manner was examined on lipid inhibition in 
3T3-L1 cells by using Oil Red O staining. Fucoidan showed high lipid inhibition activity at 
200 µg/mL concentration (P < 0.001). Lipolytic activity in adipocytes is highly dependent 
on hormone sensitive lipase (HSL), which is one of the most important targets of lipolytic 
regulation. Here, we examined the biological response of fucoidan on the protein level of 
lipolysis pathway. The expressed protein levels of total hormone sensitive lipase (HSL) 
and its activated form, phosphorylated-HSL were significantly increased at concentration 
of 200 µg/mL fucoidan. Furthermore, insulin-induced 2-deoxy-D-[
3H] glucose uptake was 
decreased up to 51% in fucoidan-treated cells as compared to control. Since increase of 
HSL and p-HSL expression and decrease of glucose uptake into adipocytes are known to 
lead to stimulation of lipolysis, our results suggest that fucoidan reduces lipid accumulation 
by stimulating lipolysis. Therefore, these results suggest that fucoidan can be useful for the 
prevention or treatment of obesity due to its stimulatory lipolysis. 
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1. Introduction 
Obesity  is  a  chronic  metabolic  disorder  caused  by  an  imbalance  between  energy  intake  and 
expenditure. It has become a major obstacle of improving human health and life quality due to the 
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known risk factors for many chronic diseases. It is characterized by hyperplasia and hypertrophy, and 
is regarded as a major factor for cardio-metabolic disturbances such as hypertension, atherosclerosis, 
type 2 diabetes and dyslipidemia [1–3]. In general, obesity is associated with the extent of adipocyte 
differentiation, intracellular lipid accumulation and lipolysis [4,5]. 
Marine brown algae have long made up a key part of the Asian diet and are also consumed in other 
parts of the world. It has often been used as a food for people who are sick and has been credited with 
health-giving  properties.  Today,  marine  brown  algae  supplements  for  human  use  are  usually 
considered  to  be  sources  of  therapeutic  benefits  [6].  Especially,  Fucoidan  is  a  sulfated  fucose 
containing polysaccharide extracted from marine brown algae [7]. During the past  years, fucoidan 
extracted from various species has been recognized to possess biological properties; anti-coagulant, 
anti-thrombotic, anti-tumor, anti-inflammatory and anti-virus activities [8]. The anti-coagulant activity 
of  sulfated  polysaccharide  from  Fucus  evanescens  was  similar  to  that  of  heparin.  Anti-coagulant 
properties of fucoidan are determined by thrombin inhibition mediated via plasma antithrombin III [9]. 
Fucoidan  from  Mekabu,  a  dietary  alga,  exerts  anti-tumor  activity  possibly  through  enhancing  the 
Th1 cell  and  NK  cell  responses  [10].  Fucoidan,  a  sulfated  polysaccharide  isolated  from  an  edible 
brown alga Undaria pinnatifida, was shown to be a potent inhibitor of the in vitro replication of herpes 
simplex virus type 1 (HSV-1) [11–13]. 
Recently, there has been increasing interest in potential biological activity against fat inhibition 
from fucoidan, which is an adipogenic reduction of fucoidan-declined lipid accumulation in adipocytes. 
Fucoidan can be used for inhibiting fat accumulation, which is mediated by decreasing aP2, ACC, and 
PPARγ  gene  expression  [14].  Fucoidan  treatment  inhibits  adipocyte  differentiation,  evidenced  by 
decreased lipid accumulation and down regulation of adipocyte markers via mitogen-activated protein 
kinase  (MAPK)  signaling  pathways.  As  of  yet,  however,  no  study  has  clearly  investigated  the 
inhibitory effects of fucoidan on lipid accumulation through the regulation of lipolysis. Lipolysis is a 
prerequisite  for lipid accumulation via the regulation of hormone sensitive lipase (HSL) as  a rate 
limiting enzyme, which is the hydrolysis of triglycerides into free fatty acids. 
In this study, we examined whether fucoidan from Fucus vesisulosus inhibits lipid accumulation in 
3T3-L1  adipocytes  via  the  stimulation  of  lipolysis.  First,  we  quantified  the  accumulation  of  lipid 
droplets in 3T3-L1 cells in a dose-dependent manner using Oil Red O staining. Second, we showed the 
stimulatory effect of fucoidan on the protein expression of HSL and its activated form, p-HSL by 
western blotting assay, which function as the key rate-limiting enzyme on lipolysis. Furthermore, we 
examined insulin-induced glucose uptake into 3T3-L1 adipocytes as a measure of lipolytic effect of 
fucoidan. Finally, we confirmed inhibitory effect of fucoidan on triglyceride accumulation in 3T3-L1 
cells.  As  a  result,  we  demonstrated  that  fucoidan  may  reduce  lipid  accumulation  through  the 
stimulation of lipolysis and may be a candidate for an anti-obesity agent. 
2. Results and Discussion 
2.1. Cell Viability and Lipid Inhibitory Effect of Fucoidan on 3T3-L1 Adipocyte Differentiation 
We first examined whether fucoidan has an influence on cell viability of 3T3 adipocytes using a  
CCK-8 assay. Fucoidan did not have toxicity at concentrations in a dose-dependent manner (Figure 1). Mar. Drugs 2011, 9  
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Figure 1. Effect of fucoidan on viability of 3T3-L1 adipocytes. Cells were treated with 
various  concentration  of  fucoidan  for  4  days.  On  day  8,  cell  viability  was  determined  
via  CCK-8  assay.  All  values  are  the  mean  ±  standard  deviation  (SD)  from  five  
independent experiments. 
 
The inhibitory effect of fucoidan on differentiation of 3T3-L1 preadipocytes was then examined  
by Oil Red O staining. The microscopic inspection of fucoidan-treated adipocytes after Oil Red O 
staining revealed a significant reduction in the lipid droplets and accumulation of intracellular lipid 
(Figure 2A). The lipid accumulation was decreased by 16.5% (P < 0.05) at 100 µg/mL and 52.2%  
(P < 0.001) at 200 µg/mL of fucoidan, respectively (Figure 2B). Triglyceride assay was performed that 
fucoidan could inhibit triglyceride accumulation in 3T3-L1 adipocytes (Figure 3). Fucoidan exhibited 
86%  decrease  in  triglyceride  accumulation  compared  to  the  control.  Therefore,  fucoidan  
showed anti-adipogenic properties as evidenced by decreased lipid and triglyceride accumulation in  
3T3-L1 cells. 
Figure 2. Effect of fucoidan on 3T3-L1 adipogenic differentiation. 3T3-L1 preadipocytes 
were treated with various concentration of fucoidan until Day 8, and change of adipocyte 
differentiation was determined with Oil Red O staining: (A) Microscopic observation of 
3T3-L1 cells; and (B) Quantification analysis by Oil Red O staining. The eluted Oil Red  
O  dye  with  isopropanol  was  quantified  by  measuring  optical  density  at  500  nm  with  
UV-spectrophotometer. Values given are the mean ± standard deviation of five independent 
experiments. Scale bar represents 100 µm (* P < 0.05, ** P < 0.001). 
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Figure 2. Cont. 
 
Figure  3.  Triglyceride  accumulation  in  3T3-L1  adipocytes  treated  with  fucoidan.  The 
triglyceride  contents  in  the  lysates  of  3T3-L1  cells  were  analyzed  by  using  the  TG-S 
reaction kit. Data represent the mean ± SD from three independent tests (** P < 0.001). 
 
2.2. Expression Level of Lipolytic Gene 
Lipolytic activity in adipocytes is highly dependent on hormone sensitive lipase (HSL), which is 
one of the most important targets of lipolytic regulation. The subsequent phosphorylation and activation 
of HSL result in an increase of the hydrolysis of stored triacylglycerol into mono-acylglycerol and free 
fatty acids [15–17]. To evaluate the effect of fucoidan on the regulation of lipolysis, we investigated  
the  protein  level  of  HSL  and  phosphorylated  HSL  (p-HSL)  by  western  blotting  analysis.  In  fully 
differentiated 3T3-L1 adipocytes, fucoidan treatment at 200 µg/mL increased HSL and p-HSL level by 
approximately 1.47 and 1.59 times as compared to the controls (Figures 4A,B). Kim group reported 
that the treatment of gensonosides or EGCG prevented obesity via the up-regulated expression of HSL 
mRNA [18]. Cha group showed that methanol extract from Luffa cylindrical (LCM) stimulates the 
lipolysis through the induction of HSL resulting in the reduced lipid accumulation [19]. Therefore, our 
results suggest that fucoidan may induce lipolysis by increasing the protein levels of HSL and p-HSL. Mar. Drugs 2011, 9  
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Figure 4. Effect of fucoidan on expressions of HSL and p-HSL. The protein expressions of 
(A) HSL and (B) p-HSL were examined by western blotting (top) and the expression levels 
were quantified by densitometry (bottom) (* P < 0.05). 
 
2.3. Inhibitory Effect of Fucoidan on Insulin-Induced Glucose Uptake 
The inhibitory activity of fucoidan on glucose uptake in 3T3-L1 adipocytes was assessed by using 
2-deoxy-D-[
3H] glucose uptake quantitative assay (Figure 5). In the absence of insulin, fucoidan had 
no significant effect. However, it demonstrated its inhibitory effect on glucose uptake. The glucose 
uptake was greatly enhanced in the presence of 10 µg/mL insulin. Insulin, which is a central hormone 
to regulate fat metabolism in the body, causes cells in adipocytes tissue to take up glucose from the 
blood, stimulating glucose utilization by its anti-lipolytic effect on adipose tissue [20]. However, the 
insulin-induced  glucose  uptake  was  decreased  by  fucoidan  at  200  µg/mL  (51%  decreases)  and 
cytochalasin B, which is a positive control for glucose uptake inhibition. Therefore, our results further 
present that fucoidan inhibits lipid accumulation by decreasing glucose uptake. 
Figure  5.  Inhibitory  effect  of  fucoidan  on  glucose  uptake  into  3T3-L1  adipocytes. 
Differentiated  3T3-L1  cells  were  incubated  with  10  µg/mL  insulin  in  the  presence  or 
absence  of  200  µg/mL  fucoidan,  and  then  assayed  for  2-deoxy-D-[
3H]  glucose  uptake.  
20 µM Cytochalasin B was used as a positive control for inhibition of glucose uptake. The  
mean ± SD from at least three replicate experiments (* P < 0.05, ** P < 0.001). 
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In  summary,  the  findings  of  this  study  clearly  demonstrated  the  inhibitory  effect  of  fucoidan 
extracted from Fucus vesisulosus on lipid accumulation in 3T3-L1 adipocytes via stimulatory lipolysis. 
The stimulation of lipolysis was mediated by increasing the protein expression of HSL and p-HSL, 
which are essential regulation factors for lipolysis, and by decreasing glucose uptake into 3T3-L1 
adipocytes. Therefore, we suggest that fucoidan is a promising candidate for an anti-obesity agent by 
blocking lipid accumulation and stimulating lipolysis. 
3. Experimental Section 
3.1. Materials 
The  preadipogenic  cell  line  3T3-L1  was  obtained  from  the  American  Type  Culture  Collection 
(ATCC,  CL-173).  Dulbecco’s  modified  Eagle  medium  (DMEM),  bovine  calf  serum  (BCS),  fetal 
bovine serum (FBS), phosphate-buffered saline (PBS) and trypsin–EDTA were acquired from Gibco 
(Gaithersburg, MD, USA). Penicillin–streptomycin, dexamethasone (DEX), 3-isobutyl-1-methylxanthine 
(IBMX),  insulin  and  Oil  Red  O  were  purchased  from  Sigma  (St,  Louis,  MO,  USA).  Fucoidan, 
extracted  from  focus  vesiculosus,  was  provided  by  Sigma  (St,  Louis,  MO,  USA).  CCK-8  was 
purchased from Daeil Lab Service, Ltd. (Seoul, Korea). 
3.2. Cell Culture and Differentiation 
3T3-L1 preadipocyte cells purchased from ATCC (Manassas, VA, USA) were cultured, maintained 
and stimulated to differentiate as described previously [16]. Cells were initially maintained in DMEM 
with  10%  BCS,  and  1%  (v/v)  penicillin-streptomycin  (100  units/mL  penicillin  and  100  µg/mL 
streptomycin) at 37 °C in 5% CO2. At 2 days post-confluence, 3T3-L1 cell differentiation was induced 
by treating confluent cells with a hormone mixture containing 10% FBS, 10 µg/mL insulin, 0.5 mM 
IBMX and 0.5 µM DEX. To investigate the effects of fucoidan on fully differentiated adipocytes, 
fucoidan concentrations of 0, 5, 10, 50, 100 and 200 µg/mL were applied to the cells. Two days later, 
the medium was placed into DMEM supplemented with only 10 µg/mL insulin and 10% FBS. The 
same concentrations of fucoidan were supplemented at two-day intervals when the culture medium 
was replenished. After adipocyte differentiation, the cells were stained with Oil Red O staining, which 
is an indicator of cell lipid content. Cells were washed with phosphate-buffered saline, fixed with 
10% buffered formalin and stained with Oil Red O solution (0.5 g in 100 mL isopropanol) for 1 h and 
observed under a microscope. For quantification, the staining solution was removed, the dye retained 
in  the  cells  was  eluted  into  isopropanol,  and  OD500  was  determined  using  a  spectrophotometer 
(UVIKON XS, SECOMAM, France). 
3.3. Cell Viability  
Cell viability was assessed using a CCK-8 assay. 3T3-L1 adipocyte cells were treated with fucoidan 
at 0, 5, 10, 50, 100, and 200 µg/mL for 4 days. After adipocyte differentiation, CCK-8 solution was 
added, and cells were incubated at 37 °C for 30 min. Finally, absorbance was measured at 450–650 nm 
to obtain the percentage of viable cells. 
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3.4. Western Blotting 
Cultured differentiated cells were lysed in an ice-cold lysis buffer (1 M Tris, 5 M NaCl, 100% NP-40, 
1 M NaF, 100 mM Na2NO4, 100 mM EDTA). Cell lysate was separated via electrophoresis on an 
8% SDS-polyacrylamide gel, followed by electrophoretic transfer to a Hybond-P PVDF membrane. 
The samples were  and blocked with 5% skim milk in TBS with 0.1% Triton X-100 (TBS-T) for  
120  min  at  room  temperature.  The  membranes  were  then  incubated  overnight  with  anti-HSL  and  
anti-phospho-HSL antibodies (1:1000 dilution, Cell signaling) in TBS-T at 4 °C. After incubation with 
horseradish peroxidase, anti-rabbit IgG antibody (1:2500, Cell signaling) was conjugated for 1 h at 
room temperature. For normalization, the membranes were reprobed with antibodies against β-actin 
(1:5000 dilution, Santa Cruz Biotechnology). Several exposure times were used to obtain the signals in 
the linear range.  
3.5. Glucose Uptake Activity Assay 
Glucose  uptake  activity  was  analyzed  by  measuring  the  uptake  of  2-deoxy-D-[
3H]  glucose,  as 
described previously. 3T3-L1 cells plated in a 24 well plate were washed three times with PBS and 
incubated in 1 mL/well warm PBS containing 10 µg/mL insulin for 30 min at 37 °C. After washing 
twice in PBS, the cells were incubated in 1mL low glucose DMEM containing cytochalasin B or 
fucoidan and 2-deoxy-D-[
3H] glucose. After 30 min, glucose uptake was terminated by washing the 
cells three times with cold PBS. The cells were lysed with 0.1 mL of 1% SDS per well at RT for 
10 min. The radioactivity  retained by the cell lysates was determined  using a scintillation counter 
(1450 MicroBeta TriLux, USA). 
3.6. Triglyceride Accumulation Content Assay 
3T3-L1 adipocytes, cultured with fucoidan at 200 µg/mL in each well of 6 well plates for 8 days, 
were harvested in 300 µL of 1% triton X-100 and then centrifuged. The triglyceride contents of the cell 
lysates were analyzed by using the TG-S reaction kit (Asan Pharm. Co., Seoul, Korea) according to the 
manufacturer’s instructions. 
3.7. Statistical Analysis 
The significant differences (* P < 0.05, ** P < 0.001) between samples were evaluated through the 
student’s t-test. 
4. Conclusions 
In  this  study,  we  showed  fucoidan  from  marine  brown  algae  inhibits  lipid  accumulation  in  
3T3-L1 adipocytes via stimulating lipolysis. The treatment of fucoidan reduced lipid accumulation in 
3T3-L1 cells in a dose-dependent manner by determined Oil Red O staining, and a 52.2% decrease 
was  observed  at  200  µg/mL  (P  <  0.05).  Fucoidan  reduces  the  lipid  accumulation  by  stimulating 
lipolysis from the enhancement of HSL and p-HSL expression. Therefore, these results suggest that 
fucoidan could be useful for prevention or treatment of obesity by its stimulatory lipolysis. Mar. Drugs 2011, 9  
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